Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
24 6월 2024 - 9:00PM
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company
decoding biology to industrialize drug discovery, will give updated
pipeline guidance to investors, analysts, and other stakeholders
during Download Day, Recursion’s investor and R&D day, on
Monday, June 24, 2024.
“Since our last Download Day, which was approximately 18 months
ago, we have seen various industries increasingly embrace AI/ML
solutions. This adoption has also played out in the drug discovery
space,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion.
“Over the past decade, we have created a strong leadership position
by building the technological and operational capabilities of our
platform in order to expand and advance our internal pipeline as
well as deliver for our external partners through the integrated
use of data, compute, and automation. We look forward to
highlighting the various aspects of the Recursion value proposition
at Download Day.”
The event will feature a number of prominent speakers, including
Jensen Huang, founder and CEO of NVIDIA, Deepak Nijhawan, M.D.,
Ph.D., UT Southwestern Distinguished Chair in Biomedical Science,
and John Marioni, Ph.D., Senior VP and Head of Computational
Sciences at Genentech.
Updated pipeline guidance:
- Seven Clinical Trial Readouts expected within approximately 18
months:
- REC-994 Cerebral Cavernous Malformation—topline Phase 2 data
readout in September 2024;
- REC-2282 Neurofibromatosis Type 2—preliminary Phase 2 data
readout in the fourth quarter of 2024;
- REC-4881 Familial Adenomatous Polyposis—preliminary Phase 2
data readout in the first half of 2025;
- REC-4881 Advanced AXIN1/APC-Mutant Cancers—preliminary Phase 2
data readout in the first half of 2025;
- REC-3964 Clostridioides difficile Infection—Phase 2 study
initiation in the fourth quarter of 2024 and preliminary data
readout by the end of 2025;
- RBM39 Advanced HR-Proficient Cancers—IND submission in the
third quarter of 2024, Phase 1/2 initiation in the fourth quarter
of 2024 and Phase 1 dose-escalation data readout by the end of
2025;
- Target Epsilon (Fibrotic Diseases)—IND submission in early 2025
and Phase 1 healthy volunteer study data readout by the end of
2025.
- Dozens of internal and partner programs in early stages with
the first LLM and causal model driven programs entering the
Recursion pipeline.
Partnership updates
- Bayer will be the first beta-user of our LOWE LLM-orchestrated
workflow software, which will be integrated across the
collaboration and offer a more exploratory, and intuitive research
environment for scientists on both sides.
- Additional updates pertaining to the Bayer partnership include:
- We initiated our first joint oncology project which is now
expected to advance rapidly towards Lead Series nomination;
and
- We are on track to complete 25 unique multi-modal data packages
that we expect to deliver in the third quarter of 2024.
Platform updates
- ADME industrialization: potential to achieve an estimated 90
times the amount of lab throughput over a manual approach.
- Built our first genome-scale transcriptomics knockout map.
- Multimodal mapping has enabled us in certain experiments to
achieve 90% success on our ability to predict compounds that failed
later disease-relevant assays in internal tests and 60% ability to
predict compounds that passed later disease-relevant assays in
internal tests.
- Helix partnership brings hundreds of thousands of unique
de-identified patient records across diverse therapeutic
areas.
About RecursionRecursion is a leading clinical
stage TechBio company decoding biology to industrialize drug
discovery. Central to its mission is the Recursion Operation System
(OS), a platform built across diverse technologies that
continuously expands one of the world’s largest proprietary
biological, chemical and patient-centric datasets. Recursion
leverages sophisticated machine-learning algorithms to distill from
its dataset a collection of trillions of searchable relationships
across biology and chemistry unconstrained by human bias. By
commanding massive experimental scale — up to millions of wet lab
experiments weekly — and massive computational scale — owning and
operating what Recursion believes is one of the fastest
supercomputers deployed in the sector, Recursion is uniting
technology, biology, chemistry and patient-centric data to advance
the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montreal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on X (formerly Twitter) and LinkedIn.
Media ContactMedia@Recursion.com
Investor ContactInvestor@Recursion.com
Forward-Looking StatementsThis document
contains information that includes or is based upon
“forward-looking statements” within the meaning of the Securities
Litigation Reform Act of 1995, including, without limitation,
Recursion’s anticipated Download Day presentations; Recursion’s
ability to decode biology and industrialize drug discovery; the
technological and operational capabilities of Recursion’s platform;
advancement of Recursion’s internal pipeline and the ability to
deliver for its external partners; the advancement of a joint
oncology project rapidly towards Lead Series nomination; Bayer
becoming the first external beta-user of LOWE and integrating
software across the collaboration; the timing for completing 25
unique multi-modal data packages; the timing of IND submissions,
clinical trial initiations, and clinical trial readouts; realizing
dozens of LLM and causal model driven programs entering the
Recursion pipeline; the performance expectations for Recursion’s
platform, including 90x of lab throughput over a manual approach,
building Recursion’s first genome-scale transcriptomics knockout
and multimodal mapping expected capabilities and achievements;
Recursion’s continuous expansion of datasets and advancement of the
future of medicine; and all other statements that are not
historical facts. Forward-looking statements may or may not include
identifying words such as “plan,” “will,” “expect,” “anticipate,”
“intend,” “believe,” “potential,” “continue,” and similar terms.
These statements are subject to known or unknown risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements, including but
not limited to: challenges inherent in pharmaceutical research and
development, including the timing and results of preclinical and
clinical programs, where the risk of failure is high and failure
can occur at any stage prior to or after regulatory approval due to
lack of sufficient efficacy, safety considerations, or other
factors; our ability to leverage and enhance our drug discovery
platform; our ability to obtain financing for development
activities and other corporate purposes; the success of our
collaboration activities; our ability to obtain regulatory approval
of, and ultimately commercialize, drug candidates; our ability to
obtain, maintain, and enforce intellectual property protections;
cyberattacks or other disruptions to our technology systems; our
ability to attract, motivate, and retain key employees and manage
our growth; inflation and other macroeconomic issues; and other
risks and uncertainties such as those described under the heading
“Risk Factors” in our filings with the U.S. Securities and Exchange
Commission, including our Annual Report on Form 10-K and Quarterly
Report on Form 10-Q. All forward-looking statements are based on
management’s current estimates, projections, and assumptions, and
Recursion undertakes no obligation to correct or update any such
statements, whether as a result of new information, future
developments, or otherwise, except to the extent required by
applicable law.
Recursion Pharmaceuticals (NASDAQ:RXRX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Recursion Pharmaceuticals (NASDAQ:RXRX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024